01:12 PM EST, 11/29/2024 (MT Newswires) -- Biogen (BIIB) and Eisai have launched Leqembi, an anti-amyloid antibody treatment for early Alzheimer's disease, in South Korea following regulatory approval in May, Biogen said late Wednesday.

Eisai Korea will distribute the drug, initially focusing on the private market with initiatives including a patient assistance program, Biogen said.

Leqembi targets amyloid-beta aggregates, reducing plaques associated with Alzheimer's and slowing disease progression, Biogen said.

Price: 160.63, Change: +0.80, Percent Change: +0.50